| ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ a Jiří MAYER. BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. Leukemia & lymphoma. England: Informa Healthcare, 2012, roč. 53, č. 8, s. 1627-1629. ISSN 1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2012.656104. |
Další formáty:
BibTeX
LaTeX
RIS
@article{979222,
author = {Šimara, Pavel and Peterková, Martina and Stejskal, Stanislav and Potěšilová, Michaela and Krontorád Koutná, Irena and Ráčil, Zdeněk and Rázga, Filip and Jurček, Tomáš and Dvořáková, Dana and Mayer, Jiří},
article_location = {England},
article_number = {8},
doi = {http://dx.doi.org/10.3109/10428194.2012.656104},
keywords = {p-CrkL; chronic myeloid leukemia; imatinib},
language = {eng},
issn = {1042-8194},
journal = {Leukemia & lymphoma},
title = {BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.},
url = {http://www.ncbi.nlm.nih.gov/pubmed/22233112},
volume = {53},
year = {2012}
}
TY - JOUR
ID - 979222
AU - Šimara, Pavel - Peterková, Martina - Stejskal, Stanislav - Potěšilová, Michaela - Krontorád Koutná, Irena - Ráčil, Zdeněk - Rázga, Filip - Jurček, Tomáš - Dvořáková, Dana - Mayer, Jiří
PY - 2012
TI - BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
JF - Leukemia & lymphoma
VL - 53
IS - 8
SP - 1627-1629
EP - 1627-1629
PB - Informa Healthcare
SN - 10428194
KW - p-CrkL
KW - chronic myeloid leukemia
KW - imatinib
UR - http://www.ncbi.nlm.nih.gov/pubmed/22233112
L2 - http://www.ncbi.nlm.nih.gov/pubmed/22233112
N2 - In this study, we assessed BCR-ABL kinase activity by measuring the protein levels of CrkL and its phosphorylated form (p-CrkL) in order to predict the clinical outcome of newly diagnosed chronic myeloid leukemia patients. CD34+ cells from these patients were collected before the start of imatinib therapy and treated in vitro with imatinib. The reduction of p-CrkL and CrkL protein levels was then measured by flow cytometry. The data were processed using three independent approaches: an assessment of a) IC50imatinib, b) p-CrkL/CrkL ratio, and c) p-CrkL ratio. The results were subsequently correlated with the clinical response of patients after 3 and 6 months of imatinib therapy. None of the three p-CrkL parameters measured in CD34+ cells was found to be predictive of clinical outcome.
ER -
ŠIMARA, Pavel, Martina PETERKOVÁ, Stanislav STEJSKAL, Michaela POTĚŠILOVÁ, Irena KRONTORÁD KOUTNÁ, Zdeněk RÁČIL, Filip RÁZGA, Tomáš JURČEK, Dana DVOŘÁKOVÁ a Jiří MAYER. BCR-ABL activity measured by 50\%{} inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response. \textit{Leukemia \&{} lymphoma}. England: Informa Healthcare, 2012, roč.~53, č.~8, s.~1627-1629. ISSN~1042-8194. Dostupné z: https://dx.doi.org/10.3109/10428194.2012.656104.
|
